Opening book details…
Can I read Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma on EtoBox?
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma by Robert J. Motzer; Thomas Powles; Michael B. Atkins; Bernard Escudier; David F. McDermott; Boris Y. Alekseev; Jae-Lyun Lee; Cristina Suarez; Daniil Stroyakovskiy; Ugo De Giorgi; Frede Donskov; Begoña Mellado; Romain Banchereau; Habib Hamidi; Omara Khan; Veronica Craine; Mahrukh Huseni; Nick Flinn; Sarita Dubey; Brian I. Rini is a Medicine article available to read on EtoBox.
What is Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma about?
## IMPORTANCE Interim analyses of the IMmotion151 trial (A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma) reported improved progression-free survival (PFS) for patients with programmed death ligand 1-positive (PD-L1 + ) metastatic renal cell carcinoma (mRCC) receiving the PD-L1 inhibitor atezolizumab plus the vascular endothelial growth factor (VEGF) inhibitor bevacizumab vs the receptor tyrosine kinase inhibitor sunitinib. Overall survival (OS) results were immature at interim analyses. OBJECTIVE To report the final OS results, safety, and exploratory biomarker analyses of the association of transcriptomic subgroups with OS in the IMmotion151 trial. DESIGN, SETTING, AND PARTICIPANTS IMmotion151 was a multicenter, open-label, phase 3 randomized clinical trial that compared the efficacy and safety of atezolizumab plus bevacizumab vs sunitinib in patients with untreated mRCC. IMmotion151 included patients from 152 academic medical centers and community oncology practices in 21 countries. Adult patients with mRCC with components of clear cell or sarcomatoid histologic features, measurable disease (ac
Who reads Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Robert J. Motzer; Thomas Powles; Michael B. Atkins; Bernard Escudier; David F. McDermott; Boris Y. Alekseev; Jae-Lyun Lee; Cristina Suarez; Daniil Stroyakovskiy; Ugo De Giorgi; Frede Donskov; Begoña Mellado; Romain Banchereau; Habib Hamidi; Omara Khan; Veronica Craine; Mahrukh Huseni; Nick Flinn; Sarita Dubey; Brian I. Rini
- Publisher
- American Medical Association (AMA)
- Published
- 2022
- Language
- EN
- Field
- Medicine (Health Sciences)